Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulipristal Acetate in Anemia Associated with Uterine Leiomyomas
NCT01553123Phase 3Withdrawn
- Sponsor
- Watson Pharmaceuticals
- Start
- Apr 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in uterine leiomyomas comparing Ulipristal with iron with Placebo (2 arms). Primary endpoint: Change from baseline in hemoglobin levels. Planned start Apr 2012; status: withdrawn.
02
Drugs
ulipristal
03
Conditions
uterine leiomyomas
Beyond the preview
Go deeper on NCT01553123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01553123.